Store launching soon — browse the catalog and join the waitlist to be notified at launch.
✦USPS Priority Mail1–3 day delivery across the U.S.Free on orders over $200
Store launching soon — browse the catalog and join the waitlist to be notified at launch.
Your cart is empty
Immunomodulatory Dipeptide
Also known as L-Glu-L-Trp (glutamyl-tryptophan)
Thymogen is the dipeptide L-glutamyl-L-tryptophan, studied in research on immune modulation and, in rodent models, on carcinogenesis endpoints.
🚀 Launching soon — join the waitlist to be notified when this product is available.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
Thymogen is the dipeptide L-glutamyl-L-tryptophan, studied in research on immune modulation and, in rodent models, on carcinogenesis endpoints.
Experimental work examines natural-killer-cell activity and immune-system behaviour under controlled conditions.
Third-party tested for purity, ID, quantity.
Thymogen is a two-residue peptide derived from thymic peptide research. Published studies have reported that the synthetic dipeptide slows age-related change and inhibits spontaneous carcinogenesis in rats, and that natural-killer-cell cytolytic activity is required for its in vivo antitumour effect.
Additional work covers oral absorption enhancement through lipid and glycosyl conjugation, and analogues evaluated in liver-damage models.
Thymogen originated in research on thymic peptide preparations, from which the active dipeptide was isolated and synthesized.
Work from the 1990s onward characterized its immunomodulatory profile across infection, oncology, and surgical research models, giving it an unusually broad literature for a dipeptide.
Research into the Glu-Trp dipeptide focuses on immunomodulation and NK-cell-dependent antitumour activity. Frameworks evaluate carcinogenesis endpoints, immune-cell function, and peptide delivery chemistry under controlled preclinical conditions.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Thymogen. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
PubMedNatural killer cell cytolytic activity is necessary for in vivo antitumor activity of the dipeptide L-glutamyl-L-tryptophan
PubMedOral absorption enhancement of dipeptide L-Glu-L-Trp-OH by lipid and glycosyl conjugation
PubMedReparative and Antioxidant Effects of New Analogues of Immunomodulator Thymogen in Experimental Model of Liver Damage
PubMedRelated
Pentadecapeptide studied for angiogenesis signaling, tissue repair pathways, and cellular regeneration research
From$50.00
$60.00
Small molecule studied for metabolic regulation, NAD pathways, and cellular energy signaling
From$40.00
Dual peptide complex studied for actin signaling, tissue regeneration pathways, and recovery system research
From$0.00
Oral peptide format studied for systemic repair signaling and gastrointestinal pathway research
$140.00
